ArticleAnnals of hematology2025
Monocyte/macrophages may exert prominent roles in macrophage activation syndrome.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Secondary Hemophagocytic lymphohistiocytosis (sHLH) is a life-threatening complication mostly occurs in adult patients with rheumatic disease, infection or lymphoma. To adequately steer treatment, clear discrimination of sHLH entities is essential. We aimed to discriminate serum biomarkers which can separate MAS from EBV associated HLH (EBV-HLH) and Lymphoma associated HLH (L-HLH) adequately. Samples from patients aged > 15 diagnosed with sHLH were analyzed using Luminex Multiple Assays (34-plex for pre-2022; 11-plex for post-2022). 209 patients were divided into three cohorts due to change of Luminex kits. Among 86 patients enrolled pre-2021, 45 patients enrolled in 2021-2022, and 78 patients enrolled post-2022. Clinical data and serum biomarkers were analyzed among MAS, EBV-HLH and L-HLH in three cohorts by Kruskal-Wallis Analysis (K-W). The Heatmap and Principal Component Analysis (PCA) were used to describe the distinctive expression of serum biomarkers in MAS, EBV-HLH and L-HLH. Other than the relationship between clinical data and biomarkers was exhibited in the Heatmap according to the Spearman's Rank Co-efficient. Furthermore Network analysis recognized the prominent biomarker in MAS. The blooding cells disproportion declined in MAS patients relative to EBV-HLH and L-HLH. Other than the level of sCD25 increased higher in EBV-HLH and L-HLH patients than MAS patients. Progressive levels of MIP-1α and IL-10 were elevated in patients with EBV-HLH and L-HLH relative to MAS. PCA and the heatmap of serum biomarkers expressions did not discriminate MAS from EBV-HLH and L-HLH efficiently. Although there was no significant difference in the relationship between clinical data and serum biomarkers, we observed the further positive association between myeloid and lymphoid-derived serum biomarkers in MAS compared with EBV-HLH and L-HLH. Further analysis revealed that IL-17 was as a prominent biomarker in pathology in MAS by Network Analysis. (1) The relationship between myeloid and lymphoid-derived biomarkers was further relevant in MAS than EBV-HLH and L-HLH. (2) The IL-17 released mostly by Th-17 cells was grouped together closely with other inflammatory mediators and we infer that IL-17 may exert an important role in MAS. These findings could guidance the efficacy of drugs targeting key cell and biomarkers specifically associated with MAS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.